COVID-19 Case Fatality Rate 29 Percent in Multiple Myeloma Patients
Increased odds of adverse outcomes seen for Hispanic/Latinos, African-American Blacks versus white patients.
Home
Shorter PSA Doubling Time Predicts Worse Outcomes in nmCRPC
In men with nonmetastatic castration-resistant prostate cancer, a PSA doubling time of less than 3 months vs 15 months or more increases the risk of metastasis, which in turn is associated with a large increase in healthcare utilization and costs.
Hyperthyroidism Therapies Not Linked to Solid Cancer Mortality
A team of investigators conducted a multicenter cohort study to determine if a relationship existed between treatment for hyperthyroidism and risk of death from solid cancer.
Glasgow Prognostic Score Predicts Adverse Pathology, Survival in UTUC
In a study, modified Glasgow prognostic score predicted nonorgan-confined disease and lymph node invasion at surgery.
Two Trials Evaluate CAR-T Cell Therapy for Relapsed/Refractory Hodgkin Lymphoma
CD30 CAR-T cell treatment after lymphodepletion may produce antitumor activity without significant toxicity in relapsed or refractory Hodgkin lymphoma.
New Evidence Supports Update of ASCO Guidelines on Prevention, Treatment of CIPN
A literature search of new studies clarifies, refutes, and expands on previous recommendations for managing new and established CIPN in patients treated with cytotoxic agents.
Children With Cancer Not Experiencing as Severe COVID-19 as Initially Feared
Studies suggest that the majority of pediatric patients with cancer and COVID-19 experience mild disease — rather than severe disease — as a result of infection with the novel virus.
Routine Use of Neoadjuvant Docetaxel Plus ADT Not Supported in Localized, High-Risk Prostate Cancer
Patients with localized prostate cancer characterized by high-risk features are at increased risk of a negative outcome following radical prostatectomy.
ALK TKI Therapy Yields Poor Outcomes in Real-World NSCLC Patients
Real-world patients with advanced ALK-positive NSCLC — especially those with brain metastases — have poor outcomes with ALK tyrosine kinase inhibitor therapies.
“Good-Risk” Group of Patients With Myeloma Saw Better Outcomes
A percentage of newly diagnosed patients had disease with lower genomic instability.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
